The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis

[1]  Bill Bynum,et al.  Lancet , 2015, The Lancet.

[2]  M. Berk,et al.  C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications , 2015, Molecular Psychiatry.

[3]  J. Alexander,et al.  Complement and blood-brain barrier integrity. , 2014, Molecular immunology.

[4]  R. Kahn,et al.  The neurobiology and treatment of first-episode schizophrenia , 2014, Molecular Psychiatry.

[5]  C. Spencer,et al.  Biological Insights From 108 Schizophrenia-Associated Genetic Loci , 2014, Nature.

[6]  R. Keefe.  The longitudinal course of cognitive impairment in schizophrenia: an examination of data from premorbid through posttreatment phases of illness. , 2014, The Journal of clinical psychiatry.

[7]  T. Chaudhuri,et al.  Role of C-reactive protein in schizophrenia: An overview , 2014, Psychiatry Research.

[8]  J. Salgado,et al.  Evidence for an Immune Role on Cognition in Schizophrenia: A Systematic Review , 2014, Current neuropharmacology.

[9]  N. Barnes,et al.  Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis , 2014, Schizophrenia Research.

[10]  Alan S. Brown,et al.  The Cytokine Model of Schizophrenia: Emerging Therapeutic Strategies , 2014, Biological Psychiatry.

[11]  Károly Mirnics,et al.  Immune System Disturbances in Schizophrenia , 2014, Biological Psychiatry.

[12]  K. Hugdahl,et al.  A Critical Review of Pro-Cognitive Drug Targets in Psychosis: Convergence on Myelination and Inflammation , 2014, Front. Psychiatry.

[13]  M. Nordentoft,et al.  The association between depressive symptoms, cognitive function, and inflammation in major depression , 2014, Brain, Behavior, and Immunity.

[14]  R. Murray,et al.  A Systematic Review of Cognitive Function in First-Episode Psychosis, Including a Discussion on Childhood Trauma, Stress, and Inflammation , 2014, Front. Psychiatry.

[15]  E. Costello,et al.  C-reactive protein and substance use disorders in adolescence and early adulthood: a prospective analysis. , 2013, Drug and alcohol dependence.

[16]  R. Kahn,et al.  Schizophrenia is a cognitive illness: time for a change in focus. , 2013, JAMA psychiatry.

[17]  F. Dickerson,et al.  Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. , 2013, Journal of affective disorders.

[18]  Yue Wang,et al.  Relationships among serum C-reactive protein, receptor for advanced glycation products, metabolic dysfunction, and cognitive impairments , 2013, BMC Neurology.

[19]  Simon C. Potter,et al.  Genome-wide Association Analysis Identifies 14 New Risk Loci for Schizophrenia , 2013, Nature Genetics.

[20]  G. Mosayebi,et al.  Serum markers of inflammation and oxidative stress in chronic opium (Taryak) smokers. , 2013, Immunology letters.

[21]  Takahiro A. Kato,et al.  Neuroinflammation in schizophrenia especially focused on the role of microglia , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[22]  H. Jørgensen,et al.  Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: A pragmatic, randomized trial☆ , 2013, European Psychiatry.

[23]  H. Meltzer.  Update on typical and atypical antipsychotic drugs. , 2013, Annual review of medicine.

[24]  S. Miyamoto,et al.  Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents , 2012, Molecular Psychiatry.

[25]  I. Melle,et al.  Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein , 2012, Schizophrenia Research.

[26]  A. Egerton,et al.  Anterior Cingulate Glutamate Levels Related to Clinical Status Following Treatment in First-Episode Schizophrenia , 2012, Neuropsychopharmacology.

[27]  M. Ota,et al.  Glutamatergic changes in the cerebral white matter associated with schizophrenic exacerbation , 2012, Acta psychiatrica Scandinavica.

[28]  M. Schwarz,et al.  Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. , 2011, Pharmacology & therapeutics.

[29]  Vidar M. Steen,et al.  The Complement Control-Related Genes CSMD1 and CSMD2 Associate to Schizophrenia , 2011, Biological Psychiatry.

[30]  H. Ehrenreich,et al.  Practice effects in healthy adults: A longitudinal study on frequent repetitive cognitive testing , 2010, BMC Neuroscience.

[31]  M. Bell,et al.  Review on Vocational Predictors: A Systematic Review of Predictors of Vocational Outcomes Among Individuals with Schizophrenia: An Update Since 1998 , 2010, The Australian and New Zealand journal of psychiatry.

[32]  D Ongur,et al.  Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder , 2010, Psychological Medicine.

[33]  S. Heishman,et al.  Meta-analysis of the acute effects of nicotine and smoking on human performance , 2010, Psychopharmacology.

[34]  Philip D. Harvey,et al.  Circumstances Under Which Practice Does Not Make Perfect: A Review of the Practice Effect Literature in Schizophrenia and Its Relevance to Clinical Treatment Studies , 2010, Neuropsychopharmacology.

[35]  H. Meltzer,et al.  Determinants of work outcome in schizophrenia and schizoaffective disorder: Role of cognitive function , 2009, Psychiatry Research.

[36]  Pall I. Olason,et al.  Common variants conferring risk of schizophrenia , 2009, Nature.

[37]  R. Heaton,et al.  What Do We Know About Neuropsychological Aspects Of Schizophrenia? , 2009, Neuropsychology Review.

[38]  M. Keshavan,et al.  Schizophrenia, “just the facts” 4. Clinical features and conceptualization , 2009, Schizophrenia Research.

[39]  K. Yaffe,et al.  The metabolic syndrome and development of cognitive impairment among older women. , 2009, Archives of neurology.

[40]  A. Blom,et al.  Complement activation and inhibition: a delicate balance. , 2009, Trends in immunology.

[41]  J. Os,et al.  ARE PSYCHOTIC PSYCHOPATHOLOGY AND NEUROCOGNITION ORTHOGONAL? A SYSTEMATIC REVIEW OF THEIR ASSOCIATIONS , 2008, Schizophrenia Research.

[42]  E. Levy,et al.  Association between cigarette smoking and C-reactive protein in a representative, population-based sample of adolescents. , 2008, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[43]  D. Garver,et al.  Compromised myelin integrity during psychosis with repair during remission in drug-responding schizophrenia. , 2008, The international journal of neuropsychopharmacology.

[44]  P. Ridker.  Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. , 2007, Nutrition reviews.

[45]  Todd Lencz,et al.  Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? , 2007, Archives of general psychiatry.

[46]  K. Hoffmann,et al.  The effects of cigarette smoking on C-reactive protein concentrations in men and women and its modification by exogenous oral hormones in women , 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[47]  F. Dickerson,et al.  C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia , 2007, Schizophrenia Research.

[48]  W. Fenton,et al.  How should DSM-V criteria for schizophrenia include cognitive impairment? , 2007, Schizophrenia bulletin.

[49]  P. Ridker.  C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. , 2007, Journal of the American College of Cardiology.

[50]  John P. Hausknecht,et al.  Retesting in selection: a meta-analysis of coaching and practice effects for tests of cognitive ability. , 2007, The Journal of applied psychology.

[51]  D. Bonifati,et al.  Role of complement in neurodegeneration and neuroinflammation. , 2007, Molecular immunology.

[52]  S. Sponheim,et al.  Does cognition predict community function only in schizophrenia?: A study of schizophrenia patients, bipolar affective disorder patients, and community control subjects , 2006, Schizophrenia Research.

[53]  Kenneth A. Bollen,et al.  Latent curve models: A structural equation perspective , 2005 .

[54]  E. Siemers,et al.  Practice effects and the use of alternate forms in serial neuropsychological testing. , 2005, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[55]  Suchitra Krishnan-Sarin,et al.  Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. , 2005, Archives of general psychiatry.

[56]  A. Kersting,et al.  Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study , 2005, Schizophrenia Research.

[57]  T. Harris,et al.  The metabolic syndrome, inflammation, and risk of cognitive decline. , 2004, JAMA.

[58]  Terry E. Duncan,et al.  An introduction to latent growth curve modeling , 2004 .

[59]  S. Rubin,et al.  Inflammatory markers and cognition in well-functioning African-American and white elders , 2003, Neurology.

[60]  Ravi S. Menon,et al.  Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. , 2002, The American journal of psychiatry.

[61]  M. Matsui,et al.  [The Japanese version of RBANS (Repeatable Battery for the Assessment of Neuropsychological Status)]. , 2002, No to shinkei = Brain and nerve.

[62]  F. Dickerson,et al.  Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia. , 2002, The American journal of psychiatry.

[63]  J. Gold,et al.  Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity. , 1999, The American journal of psychiatry.

[64]  C. Mold,et al.  Regulation of complement activation by C-reactive protein. , 1999, Immunopharmacology.

[65]  C. Randolph,et al.  The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. , 1998, Journal of clinical and experimental neuropsychology.

[66]  Rex B. Kline,et al.  Principles and Practice of Structural Equation Modeling , 1998 .

[67]  Michael F. Green,et al.  What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.

[68]  Jean Addington,et al.  A depression rating scale for schizophrenics , 1990, Schizophrenia Research.

[69]  S. Deodhar,et al.  C-reactive protein: the best laboratory indicator available for monitoring disease activity. , 1989, Cleveland Clinic journal of medicine.

[70]  M. Egan,et al.  Schizophrenia, just the facts What do we know, how well do we know it? , 1988, Schizophrenia Research.

[71]  Jacob Cohen,et al.  Applied multiple regression/correlation analysis for the behavioral sciences , 1979 .

[72]  G. Bartzokis,et al.  The early longitudinal course of cognitive deficits in schizophrenia. , 2014, The Journal of clinical psychiatry.

[73]  R. Kahn,et al.  Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. , 2014, Schizophrenia bulletin.

[74]  R. Kline.  Principles and practice of structural equation modeling, 3rd ed. , 2011 .

[75]  H. Jørgensen,et al.  Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. , 2010, BMC psychiatry.

[76]  C. Randolph,et al.  Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) , 2009 .

[77]  L. Krabbendam,et al.  ARE PSYCHOTIC PSYCHOPATHOLOGY AND NEUROCOGNITION ORTHOGONAL? A SYSTEMATIC REVIEW OF THEIR ASSOCIATIONS , 2008, Schizophrenia Research.

[78]  D. Braff,et al.  Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? , 2000, Schizophrenia bulletin.

[79]  R. Drake,et al.  Assessing substance use disorder in persons with severe mental illness. , 1996, New directions for mental health services.

[80]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[81]  K. Johnson.  An Update. , 1984, Journal of food protection.